AXOVIA THERAPEUTICS
Axovia is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers.
AXOVIA THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
1999-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.axoviatherapeutics.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Mobile Non Scaleable Content British Server Location
Similar Organizations
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Zonova
Zonova develops veterinary devices to prevent infections and reduce antibiotic use.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.axoviatherapeutics.com
- Host name: fondor-lon2.krystal.uk
- IP address: 77.72.1.51
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Axovia Therapeutics"
Home - Axovia Therapeutics
Axovia’s Solution How Axovia was Founded. After decades of helping people with ciliopathies to manage their medical conditions without dedicated treatments, Professor Phil Beales and Dr. …See details»
Axovia Therapeutics - Crunchbase Company Profile
Axovia is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families, and caregivers.See details»
About - Axovia Therapeutics
The company is positioned to initiate clinical studies for its lead program for Bardet-Biedl Syndrome (BBS), AXV-101, in mid-2025 based on robust preclinical efficacy and safety data, …See details»
Axovia Therapeutics - LinkedIn
Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head …See details»
Axovia Therapeutics - VentureRadar
Website: https://axoviatherapeutics.com. Develops transformative therapies targeting ciliopathies, focusing on gene therapy programs for severe aspects like early onset blindness and …See details»
Axovia Therapeutics - Overview, News & Similar companies
Who is Axovia Therapeutics. Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing th e …See details»
Org Chart Axovia Therapeutics - The Official Board
Jul 27, 2024 www.axoviatherapeutics.com. has 2 executives - and belongs to Jaguar Gene Therapy +44 203 856 4800; Add an executive. Axovia Therapeutics News . Anything missing? …See details»
Our Science and Approach - Axovia Therapeutics
Our Commitment to Ciliopathies . After decades of helping people with ciliopathies to manage medical conditions without dedicated treatments, Prof. Philip Beales and Dr. Victor Hernandez co-founded Axovia to develop …See details»
AXOVIA THERAPEUTICS LTD - Companies House
AXOVIA THERAPEUTICS LTD - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business …See details»
Axovia Therapeutics: Drug pipelines, Patents, Clinical trials - Synapse
Jul 4, 2023 Explore Axovia Therapeutics with its drug pipeline, therapeutic area, technology platform, 1 news, Disease Domain:Nervous System Diseases, Technology Platform:AAV …See details»
Axovia Therapeutics Company Profile 2024: Valuation, …
Axovia Therapeutics General Information Description. Developer of gene therapies designed to target the key aspects of ciliopathies. The company's therapies use the Adeno-Associated Virus (AAV) technology to treat the root …See details»
ALSA Ventures launches novel Gene Therapy portfolio company
Sep 19, 2023 Developing the first gene therapy to treat diseases caused by cilia dysfunction; AXV101 targets retinal dystrophy for Bardet-Biedl Syndrome (BBS) patientsSee details»
Axovia Therapeutics - Products, Competitors, Financials, …
A Race Against Blindness PHOENIX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- A Race Against Blindness, a nonprofit organization dedicated to funding sight-saving research for children, is …See details»
Axovia Therapeutics - Company Profile - Tracxn
Oct 24, 2024 Axovia Therapeutics ranks 17th among 27 active competitors. 11 of its competitors are funded while 5 have exited. Overall, Axovia Therapeutics and its competitors have raised …See details»
Renowned Geneticist Philip Beales Launches Axovia Therapeutics …
Feb 25, 2021 To learn more about Axovia, visit https://axoviatherapeutics.com and follow the company on LinkedIn. About Jaguar Gene Therapy. Jaguar Gene Therapy, LLC is …See details»
Axovia Therapeutics Announces Presentation of Preclinical
Oct 5, 2024 Title: AXV-101, a New Codon-Optimized BBS1 AAV9 Vector Halts Photoreceptor and Outer Nuclear Retinal Layer Organization Degeneration in a Dose-Dependent Manner …See details»
alsaventures
· Developing the first gene therapy to treat diseases caused by cilia dysfunction · AXV101 targets retinal dystrophy for Bardet-Biedl Syndrome (BBS) patientsSee details»
Axovia Therapeutics Announces Presentation of Preclinical Data ...
London, UK – May 10, 2024 – Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, announced the presentation …See details»
News at Axovia Therapeutics - The Official Board
Discover the organization charts of your favorite companies. List of the companies; Movements by industry; Executives. Spot the influential executives using our search tools. Tips for your …See details»
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint …
Oct 24, 2024 Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome . BOSTON and LONDON, October 24, 2024 – …See details»